Next-generation biosensors for drug discovery and life sciences

The Creoptix® WAVEsystem
Get superior affinity and kinetic data, even for the most challenging samples.

  • Measure interactions, not interference

    WAVEcore®

    Engineered around a proprietary Grating-Coupled Interferometry (GCI) technology, the Creoptix® WAVE system builds on waveguide interferometry to achieve superior resolution in signal and time. With low limits of detection, the WAVEsystem generates accurate kinetic rates, affinity constants, and concentrations of label-free biomolecular interactions, even at low analyte abundance, with no loss of definition.

    WAV Edelta square web landscape
  • A sensor chip for every need

    WAVEchip®

    WAVEchip®- Innovative design and patented microfluidic cartridge to support crude samples, pathogenic samples, harsh solvents, and large particles up to 1000 nm normally only achieved with plate-based assays for kinetic analysis not possible before

    WAV Echip web landscape 3
  • It's how we see light

    Grating-Coupled Interferometry

    A distinguishing advantage of the WAVE is the patented Grating Coupled Interferometry (GCI) design. GCI is based on waveguide interferometry to determine kinetics, affinity, and concentrations of the interacting molecules.

    GCI CX Graph

Biomolecular Interaction Analysis - Creoptix® WAVEsystem

Applications

Study real-time biological interactions involving fragment, small molecules, peptides, membrane proteins, biologics and other molecules even in crude reaction mixtures and biofluids like undiluted serum and plasma.

COVID-19 Research

It’s through innovation and technologies like the Creoptix® WAVEsystem that advance discovery and understanding. Find out more here.

Explore the benefits of the Creoptix® WAVEsystem and its applications

Download latest TechNotes

Find all TechNotes for download here.

  • Screening of crude reaction mixtures

    In this TechNote we show how the WAVEsystem provides a reliable environment to support optimisation of hits in fragment-based drug discovery. With high sensitivity and robust microfluidics, the WAVEsystem offers kinetic data in excellent agreement with Biacore T200 measurements. This is illustrated through a retrospectively measured Vernalis campaign to identify selective, potent inhibitors of Pyruvate Dehydrogenase Kinase 2 (PDHK2) and Heat Shock Protein 90 (HSP90).

  • Pushing the boundaries in pharmaceutical hit discovery with the novel waveRAPID® kinetic assay

    In this TechNote, conducted by an HTS drug discovery group of our customer Idorsia Pharmaceuticals Ltd, we demonstrate the power of waveRAPID in streamlining the kinetic characterization of large numbers of drug hit compounds, with results comparable to traditional SPR and high reproducibility.

The Creoptix’ WAVE technology aids us best in discovering better drug molecules

Nicolas Bocquet, Senior Scientist

Nicolas Bocquet, Senior Scientist,

leadXpro